Free Trial
NASDAQ:IMCR

Immunocore (IMCR) Stock Price, News & Analysis

Immunocore logo
$33.01 +0.26 (+0.79%)
As of 07/3/2025 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immunocore Stock (NASDAQ:IMCR)

Key Stats

Today's Range
$32.60
$33.06
50-Day Range
$27.69
$38.65
52-Week Range
$23.15
$41.54
Volume
121,185 shs
Average Volume
347,637 shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.89
Consensus Rating
Moderate Buy

Company Overview

Immunocore Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

IMCR MarketRank™: 

Immunocore scored higher than 48% of companies evaluated by MarketBeat, and ranked 1618th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Immunocore has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunocore's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunocore is -76.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunocore is -76.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunocore has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunocore's valuation and earnings.
  • Percentage of Shares Shorted

    17.19% of the float of Immunocore has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunocore has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunocore has recently increased by 4.37%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Immunocore does not currently pay a dividend.

  • Dividend Growth

    Immunocore does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.19% of the float of Immunocore has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunocore has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunocore has recently increased by 4.37%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Immunocore has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Immunocore this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for IMCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunocore insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunocore's insider trading history.
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
IMCR Immunocore Holdings plc - Seeking Alpha
See More Headlines

IMCR Stock Analysis - Frequently Asked Questions

Immunocore's stock was trading at $29.50 at the beginning of the year. Since then, IMCR stock has increased by 11.9% and is now trading at $33.01.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) released its quarterly earnings results on Wednesday, May, 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. Immunocore's revenue was up 33.6% compared to the same quarter last year.

Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/07/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
320
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.89
High Stock Price Target
$100.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+78.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.09 million
Pretax Margin
-6.83%

Debt

Sales & Book Value

Annual Sales
$310.20 million
Price / Cash Flow
N/A
Book Value
$7.20 per share
Price / Book
4.58

Miscellaneous

Free Float
45,010,000
Market Cap
$1.66 billion
Optionable
Optionable
Beta
0.77
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:IMCR) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners